References analysis of the Wikipedia article "Apolipoproteína A5" in the Galician version

doi.org

dx.doi.org

Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM (outubro de 2001). "An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing". Science 294 (5540): 169–73. Bibcode:2001Sci...294..169P. PMID 11588264. doi:10.1126/science.1064852.

van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, Chamuleau RA (novembro de 2001). "Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration". The Journal of Biological Chemistry 276 (48): 44512–20. PMID 11577099. doi:10.1074/jbc.M106888200.

Nilsson SK, Christensen S, Raarup MK, Ryan RO, Nielsen MS, Olivecrona G (setembro de 2008). "Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families". The Journal of Biological Chemistry 283 (38): 25920–7. PMC 2533778. PMID 18603531. doi:10.1074/jbc.M802721200.

Xu C, Bai R, Zhang D, Li Z, Zhu H, Lai M, Zhu Y (2013-01-01). "Effects of APOA5 -1131T>C (rs662799) on fasting plasma lipids and risk of metabolic syndrome: evidence from a case-control study in China and a meta-analysis". PLOS ONE 8 (2): e56216. Bibcode:2013PLoSO...856216X. PMC 3585417. PMID 23468858. doi:10.1371/journal.pone.0056216.

Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS (xuño de 2015). "Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials". Lancet 385 (9984): 2264–71. PMC 4608367. PMID 25748612. doi:10.1016/S0140-6736(14)61730-X.

Sharma V, Ryan RO, Forte TM (maio de 2012). "Apolipoprotein A-V dependent modulation of plasma triacylglycerol: a puzzlement". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1821 (5): 795–9. PMC 3319174. PMID 22209939. doi:10.1016/j.bbalip.2011.12.002.

Guardiola M, Alvaro A, Vallvé JC, Rosales R, Solà R, Girona J, Serra N, Duran P, Esteve E, Masana L, Ribalta J (setembro de 2012). "APOA5 gene expression in the human intestinal tissue and its response to in vitro exposure to fatty acid and fibrate". Nutrition, Metabolism, and Cardiovascular Diseases 22 (9): 756–62. PMID 21489765. doi:10.1016/j.numecd.2010.12.003.

O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, Schultze AE, Konrad RJ (febreiro de 2005). "The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins". Clinical Chemistry 51 (2): 351–9. PMID 15528295. doi:10.1373/clinchem.2004.040824.

Nilsson SK, Heeren J, Olivecrona G, Merkel M (novembro de 2011). "Apolipoprotein A-V; a potent triglyceride reducer". Atherosclerosis 219 (1): 15–21. PMID 21831376. doi:10.1016/j.atherosclerosis.2011.07.019.

Beckstead JA, Oda MN, Martin DD, Forte TM, Bielicki JK, Berger T, Luty R, Kay CM, Ryan RO (agosto de 2003). "Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis". Biochemistry 42 (31): 9416–23. PMID 12899628. doi:10.1021/bi034509t.

Nilsson SK, Lookene A, Beckstead JA, Gliemann J, Ryan RO, Olivecrona G (marzo de 2007). "Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family". Biochemistry 46 (12): 3896–904. PMID 17326667. doi:10.1021/bi7000533.

van der Vliet HN, Schaap FG, Levels JH, Ottenhoff R, Looije N, Wesseling JG, Groen AK, Chamuleau RA (agosto de 2002). "Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice". Biochemical and Biophysical Research Communications 295 (5): 1156–9. PMID 12135615. doi:10.1016/s0006-291x(02)00808-2.

Qu S, Perdomo G, Su D, D'Souza FM, Shachter NS, Dong HH (xullo de 2007). "Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice". Journal of Lipid Research 48 (7): 1476–87. PMC 2665252. PMID 17438339. doi:10.1194/jlr.M600498-JLR200.

Helleboid-Chapman A, Nowak M, Helleboid S, Moitrot E, Rommens C, Dehondt H, Héliot L, Drobecq H, Fruchart-Najib J, Fruchart JC (2009-01-01). "Apolipoprotein A-V modulates insulin secretion in pancreatic beta-cells through its interaction with midkine". Cellular Physiology and Biochemistry 24 (5–6): 451–60. PMID 19910685. doi:10.1159/000257484.

Hubacek JA, Skodová Z, Adámková V, Lánská V, Poledne R (decembro de 2005). "Sex-specific effect of APOAV variant (Val153>Met) on plasma levels of high-density lipoprotein cholesterol". Metabolism 54 (12): 1632–5. PMID 16311097. doi:10.1016/j.metabol.2005.06.012.

Hubacek JA, Wang WW, Skodová Z, Adámková V, Vráblík M, Horínek A, Stulc T, Ceska R, Talmud PJ (2008). "APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels". Clinical Chemistry and Laboratory Medicine 46 (6): 773–7. PMID 18601597. doi:10.1515/CCLM.2008.160.

Melegh BI, Duga B, Sümegi K, Kisfali P, Maász A, Komlósi K, Hadzsiev K, Komoly S, Kosztolányi G, Melegh B (2012). "Mutations of the apolipoprotein A5 gene with inherited hypertriglyceridaemia: review of the current literature". Current Medicinal Chemistry 19 (36): 6163–70. PMID 23150946. doi:10.2174/092986712804485719.

Sidore C, Busonero F, Maschio A, Porcu E, Naitza S, Zoledziewska M, et al. (novembro de 2015). "Genome sequencing elucidates Sardinian genetic architecture and augments association analyses for lipid and blood inflammatory markers". Nature Genetics 47 (11): 1272–81. PMC 4627508. PMID 26366554. doi:10.1038/ng.3368.

Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S (maio de 2011). "Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association". Circulation 123 (20): 2292–333. PMID 21502576. doi:10.1161/CIR.0b013e3182160726.

Hubacek JA (outubro de 2016). "Apolipoprotein A5 fifteen years anniversary: Lessons from genetic epidemiology". Gene 592 (1): 193–9. PMC 7108956. PMID 27496343. doi:10.1016/j.gene.2016.07.070.

Liu CF, Yang QF, Chen XL, Liu CY (outubro de 2012). "Apolipoprotein a5 gene polymorphism and risk for metabolic syndrome: a meta-analysis". Genetic Testing and Molecular Biomarkers 16 (10): 1241–5. PMID 22905904. doi:10.1089/gtmb.2012.0183.

Jiang CQ, Liu B, Cheung BM, Lam TH, Lin JM, Li Jin Y, Yue XJ, Ong KL, Tam S, Wong KS, Tomlinson B, Lam KS, Thomas GN (novembro de 2010). "A single nucleotide polymorphism in APOA5 determines triglyceride levels in Hong Kong and Guangzhou Chinese". European Journal of Human Genetics 18 (11): 1255–60. PMC 2987477. PMID 20571505. doi:10.1038/ejhg.2010.93.

Lee KH, Kim OY, Lim HH, Lee YJ, Jang Y, Lee JH (novembro de 2010). "Contribution of APOA5-1131C allele to the increased susceptibility of diabetes mellitus in association with higher triglyceride in Korean women". Metabolism 59 (11): 1583–90. PMID 20303129. doi:10.1016/j.metabol.2010.02.008.

Yin YW, Sun QQ, Wang PJ, Qiao L, Hu AM, Liu HL, Wang Q, Hou ZZ (2014-01-01). "Genetic polymorphism of apolipoprotein A5 gene and susceptibility to type 2 diabetes mellitus: a meta-analysis of 15,137 subjects". PLOS ONE 9 (2): e89167. Bibcode:2014PLoSO...989167Y. PMC 3929635. PMID 24586566. doi:10.1371/journal.pone.0089167.

Yang Y, Walijee SM, Jin J, Zhao SP, Peng DQ (2012). "Serum apolipoprotein A-V in patients with coronary artery disease and its association with triglyceride". Journal of Clinical Lipidology 6 (5): 462–8. PMID 23009782. doi:10.1016/j.jacl.2012.02.004.

Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J (maio de 2010). "Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies". Lancet 375 (9726): 1634–9. PMC 2867029. PMID 20452521. doi:10.1016/S0140-6736(10)60545-4.

Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC (novembro de 2002). "Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels". Human Molecular Genetics 11 (24): 3031–8. PMID 12417524. doi:10.1093/hmg/11.24.3031.

Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, Adiconis X, Ordovas JM (decembro de 2003). "The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore". Journal of Lipid Research 44 (12): 2365–73. PMID 12951359. doi:10.1194/jlr.M300251-JLR200.

Hubacek JA, Skodová Z, Adámková V, Lánská V, Poledne R (febreiro de 2004). "The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction". Clinical Genetics 65 (2): 126–30. PMID 14984471. doi:10.1111/j.0009-9163.2004.00199.x.

Lai CQ, Corella D, Demissie S, Cupples LA, Adiconis X, Zhu Y, Parnell LD, Tucker KL, Ordovas JM (maio de 2006). "Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham Heart Study". Circulation 113 (17): 2062–70. PMID 16636175. doi:10.1161/CIRCULATIONAHA.105.577296.

Liu Y, Ordovas JM, Gao G, Province M, Straka RJ, Tsai MY, Lai CQ, Zhang K, Borecki I, Hixson JE, Allison DB, Arnett DK (febreiro de 2009). "Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study". Pharmacogenetics and Genomics 19 (2): 161–9. PMC 2733171. PMID 19057464. doi:10.1097/FPC.0b013e32831e030e.

Hubacek JA, Adamkova V, Prusikova M, Snejdrlova M, Hirschfeldova K, Lanska V, Ceska R, Vrablik M (xuño de 2009). "Impact of apolipoprotein A5 variants on statin treatment efficacy". Pharmacogenomics 10 (6): 945–50. PMID 19530961. doi:10.2217/pgs.09.17.

Sánchez-Moreno C, Ordovás JM, Smith CE, Baraza JC, Lee YC, Garaulet M (marzo de 2011). "APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population". The Journal of Nutrition 141 (3): 380–5. PMC 3040902. PMID 21209257. doi:10.3945/jn.110.130344.

Hishida A, Morita E, Naito M, Okada R, Wakai K, Matsuo K, Nakamura K, Takashima N, Suzuki S, Takezaki T, Mikami H, Ohnaka K, Watanabe Y, Uemura H, Kubo M, Tanaka H, Hamajima N (2012). "Associations of apolipoprotein A5 (APOA5), glucokinase (GCK) and glucokinase regulatory protein (GCKR) polymorphisms and lifestyle factors with the risk of dyslipidemia and dysglycemia in Japanese - a cross-sectional data from the J-MICC Study". Endocrine Journal 59 (7): 589–99. PMID 22517333. doi:10.1507/endocrj.ej11-0310.

Hubacek JA, Peasey A, Kubinova R, Pikhart H, Bobak M (marzo de 2014). "The association between APOA5 haplotypes and plasma lipids is not modified by energy or fat intake: the Czech HAPIEE study". Nutrition, Metabolism, and Cardiovascular Diseases 24 (3): 243–7. PMC 4357849. PMID 24462044. doi:10.1016/j.numecd.2013.08.008.

Schaefer JR, Sattler AM, Hackler B, Kurt B, Hackler R, Maisch B, Soufi M (novembro de 2004). "Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5 S19W mutation as a cofactor". Clinical Chemistry 50 (11): 2214. PMID 15502102. doi:10.1373/clinchem.2004.037689.

nih.gov

ncbi.nlm.nih.gov

"Entrez Gene: APOA5 apolipoprotein A-V".

mieg@ncbi.nlm.nih.gov, Danielle Thierry-Mieg and Jean Thierry-Mieg, NCBI/NLM/NIH. "AceView: Gene:APOA5, a comprehensive annotation of human, mouse and worm genes with mRNAs or ESTsAceView.". www.ncbi.nlm.nih.gov. Consultado o 2016-10-11.

Manpuya MW, Guo J, Zhao Y (marzo de 2001). "The relationshio between plasma apolipoprotein A-IV levels and coronary heart disease". Chinese Medical Journal 114 (3): 275–9. PMID 11780313.

Apolipoproteína A5 (Galician Wikipedia)

archive.org

biogps.org

doi.org

dx.doi.org

harvard.edu

adsabs.harvard.edu

nih.gov

ncbi.nlm.nih.gov

unt.edu

digital.library.unt.edu

zenodo.org